Summary: For HD-ISS Stage 2 and Stage 3 participants, whole-brain volume shows significant association with clinical change for all four clinical variables examined here. For caudate and putamen volume, the association depended on the clinical variable. Our results provide further evidence on the use of volume change as a surrogate endpoint.
Summary: This poster shows our further investigation on the amyloid PET differences between Black and White participants in the GAP Bio-Hermes study and to better understand the relationship between Aβ+ status from visual read and quantitative SUVR.
Summary: We developed and validated scalable and robust methods for automated volumetric analysis of brain white matter hyperintensities (T2 lesions) and regions of interest in multiple sclerosis.
Lammert Albers, Chief Commercial Officer of the Global Alzheimer's Platform Foundation talks with John Dwyer, President of the foundation, and our Chief Scientific Officer, Robin Wolz about the impact of this study diversity on current and future research and the opportunities at hand at the upcoming CTAD Clinical Trials on Alzheimer's Disease 2023 conference in Boston.
We discuss our latest work to evaluate a fully automated image analysis pipeline to process vesicular monoamine transporters type 2 (VMAT2) [18F]AV-133 tracer positron emission tomography (PET) images, by comparison with a methodology requiring manual intervention.
1-8 of 131 results